Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Optimizing Present and Future Therapeutic Choices for Treatment and Management...
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Optimizing Present and Future Therapeutic Choices for Treatment and Management of Chronic Inflammatory Bowel Diseases—2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (25 July 2025) | Viewed by 2623

Special Issue Editor

Dr. Lorenzo Bertani

E-Mail Website
Guest Editor
Department of General Surgery and Gastroenterology, Tuscany Northwest ASL—Pontedera Hospital, 56025 Pontedera, Italy
Interests: inflammatory bowel diseases; biomarkers; clinical gastroenterology; translational medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The management of inflammatory bowel diseases (IBDs) has been revolutionized in recent years due to the approval of several new therapeutic options involving new inflammation pathways.

However, we must understand how to choose the correct drug for a patient. The main goal of future IBD research would be to identify new drug-specific biomarkers, which is similar to oncological management.

We invite you to visit our website to access the first volume of this Special Issue, which is available at the following link:

https://www.mdpi.com/journal/jcm/special_issues/X86D52SV7A

This Special Issue, in the Journal of Clinical Medicine, aims to place a spotlight on studies that are able to improve our knowledge of IBDs.

Dr. Lorenzo Bertani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Inflammatory Bowel Diseases(IBD)
  • JAK inhibitors
  • mucosal healing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2719 KB  
Article
Age as a Predictor of Serum Tumor Necrosis Factor Antagonist Drug and Antidrug Antibody Concentrations in Inflammatory Bowel Disease—A Nationwide Cohort Study
by Mohammad Shehab and Fatema Alrashed
J. Clin. Med. 2025, 14(4), 1057; https://doi.org/10.3390/jcm14041057 - 7 Feb 2025
Viewed by 1058
Abstract
Background/Objectives: Tumor necrosis factor antagonists (anti-TNFs) have been shown to be an effective treatment for inflammatory bowel disease (IBD). Several factors are associated with anti-TNF treatment failure. This study aims to explore the impact of age on serum concentrations of anti-TNF drugs [...] Read more.
Background/Objectives: Tumor necrosis factor antagonists (anti-TNFs) have been shown to be an effective treatment for inflammatory bowel disease (IBD). Several factors are associated with anti-TNF treatment failure. This study aims to explore the impact of age on serum concentrations of anti-TNF drugs and antidrug antibodies (ADAbs). Methods: We retrospectively reviewed patients’ charts from July 2018 until September 2024 across seven medical centers. Patients with an established diagnosis of IBD receiving infliximab or adalimumab were included. The primary outcome of this study was the effect of age on the anti-TNFs serum drug concentration and ADAb levels. Linear regression was performed to explore the relationship between age and serum anti-TNF drug and ADAb levels. Results: 1093 patients were included in our cohort. In patients receiving infliximab, there was a significant association between older age and increasing ADAbs levels (p = 0.036), whereas in patients treated with adalimumab, there was no significant relationship between older age and ADAb levels (p = 0.771). There was no significant relationship between age and adalimumab serum concentration (p = 0.54). When stratified by age, patients taking infliximab who were >30 years of age developed more ADAbs compared to those aged ≤30 (p = 0.003). Conclusions: Patients older than 30 years of age receiving infliximab monotherapy have higher ADAbs and lower serum drug concentrations than younger patients. There was no statistically significant difference in ADAbs and serum drug concentrations among patients receiving infliximab combination therapy or adalimumab monotherapy. Full article
(This article belongs to the Special Issue Optimizing Present and Future Therapeutic Choices for Treatment and Management of Chronic Inflammatory Bowel Diseases—2nd Edition)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

20 pages, 1113 KB  
Review
Emerging Therapies in Inflammatory Bowel Disease: A Comprehensive Review
by John K. Appiah, Umar Hayat, Nikita Garg, Richeal Asante, Evans Donneyong, Muhammad U. Haider, Pranav Patel, Zubair Khan and Ali A. Siddiqui
J. Clin. Med. 2025, 14(17), 6119; https://doi.org/10.3390/jcm14176119 - 29 Aug 2025
Viewed by 1041
Abstract
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), represents a significant challenge in gastroenterology due to its chronic nature, unpredictable course, and impact on patients’ quality of life. The therapeutic landscape for IBD has evolved significantly with the advent [...] Read more.
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), represents a significant challenge in gastroenterology due to its chronic nature, unpredictable course, and impact on patients’ quality of life. The therapeutic landscape for IBD has evolved significantly with the advent of biologic agents targeting specific immune pathways. However, limitations, including partial efficacy, side effects, and development of resistance, highlight the ongoing need for innovative treatment approaches. This review explores emerging therapies in IBD, including novel biologics, small molecules, microbiome-based therapies, and gene and stem cell therapies. The article summarizes their mechanisms of action, clinical efficacy, safety profiles, and potential future directions in IBD management. Methods: This comprehensive narrative review synthesizes current knowledge and emerging developments in inflammatory bowel disease (IBD) therapeutics. Literature was identified through targeted selection of high-quality sources, including pivotal randomized controlled trials, systematic reviews and meta-analyses, regulatory approval documents, and clinical practice guidelines from major gastroenterology societies. Emphasis was placed on recent publications (2020–2024) to capture the rapidly evolving therapeutic landscape, with particular attention to FDA/EMA-approved therapies and promising late-stage investigational agents. Sources were prioritized based on clinical relevance, study quality, and regulatory status. This narrative approach was selected to provide comprehensive coverage of diverse therapeutic modalities spanning conventional treatments to cutting-edge techniques, including biologics, small molecules, microbiome-based therapies, gene therapy, and stem cell treatments. The review acknowledges the inherent limitations of non-systematic literature selection while prioritizing clinical utility and educational value for healthcare providers managing IBD patients in contemporary practice. Full article
(This article belongs to the Special Issue Optimizing Present and Future Therapeutic Choices for Treatment and Management of Chronic Inflammatory Bowel Diseases—2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop